Across TCGA pan-cancer cohorts, XRCC6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated XRCC6 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher XRCC6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated XRCC6 expression acts as an unfavorable survival marker, although some lineages such as COAD and PDAC show a favorable association.

HNSC, COAD, and PDAC are the cancer types where XRCC6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.903	1.000	.004	40	view →
COAD	DFS	Tertile	All	1.000	0.891	.045	18	view →
PDAC	DFS	Quartile	All	0.510	0.296	.008	10	view →
UCEC	DFS	Median	III,IV	0.460	0.889	.044	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: XRCC6 tumor-vs-normal RNA expression · all XRCC6 data types